Premium
Migraine Prophylaxis With Topiramate and Bone Health in Women
Author(s) -
Ali Imran I.,
Herial Nabeel A.,
Orris Megan,
Horrigan Terrance,
Tietjen Gretchen E.
Publication year - 2011
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.2011.01863.x
Subject(s) - topiramate , medicine , migraine , bone health , osteopenia , headaches , pediatrics , zolmitriptan , epilepsy , osteoporosis , surgery , psychiatry , bone mineral , receptor , sumatriptan , agonist
Antiepileptic drugs (AEDs) are commonly used for prevention of migraine headaches. Bone loss is a known complication, particularly associated with use of older AEDs. Topiramate is a newer AED, widely used for migraine prevention, but no evidence is currently available on its effect on bone metabolism. In a clinic‐based pilot study, we evaluated bone health by examining biochemical and radiological markers of bone metabolism, in women with migraine. Osteopenia was noted in 53% of the patients and was associated with the duration of exposure to topiramate ( P = .04).